Trials / Completed
CompletedNCT00666783
An Efficacy and Safety Study of Palonosetron in Preventing Chemotherapy-Induced Nausea and Vomiting (CINV) in the Chinese Cancer Patients
A Phase II, Multicenter,Double-Blind, Randomized Trial of Palonosetron Compared With Granisetron in Preventing Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting in the Chinese Cancer Patients
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 208 (actual)
- Sponsor
- Xijing Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This clinical study was designed to demonstrate that a single, intravenous dose of palonosetron 0.25 mg was not inferior to granisetron 3 mg in preventing acute and delayed CINV and was also well tolerated in the Chinese cancer patients.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | palonosetron | receive a single, intravenous dose of palonosetron 0.25 mg, 30 minutes before receiving highly emetogenic chemotherapy. |
| DRUG | Granisetron | receive a single, intravenous dose of granisetron 3 mg, 30 minutes before chemotherapy. |
Timeline
- First posted
- 2008-04-25
- Last updated
- 2008-04-25
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT00666783. Inclusion in this directory is not an endorsement.